Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

In vitro CFTR folding assays.

Stidham RD, Wigley WC, Thomas PJ.

Methods Mol Med. 2002;70:311-22. No abstract available.

PMID:
11917534
2.

Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure.

Lewis HA, Zhao X, Wang C, Sauder JM, Rooney I, Noland BW, Lorimer D, Kearins MC, Conners K, Condon B, Maloney PC, Guggino WB, Hunt JF, Emtage S.

J Biol Chem. 2005 Jan 14;280(2):1346-53.

3.

CFTR folding and maturation in cells.

Benharouga M, Sharma M, Lukacs GL.

Methods Mol Med. 2002;70:229-43. No abstract available.

PMID:
11917526
4.

Introduction to section III: biochemical methods to study CFTR protein.

Amaral MD, Lukacs GL.

Methods Mol Biol. 2011;741:213-8. doi: 10.1007/978-1-61779-117-8_14.

PMID:
21594787
5.

Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting.

Powell K, Zeitlin PL.

Adv Drug Deliv Rev. 2002 Dec 5;54(11):1395-408. Review.

PMID:
12458151
6.
7.

CFTR expression and ER-associated degradation in yeast.

Zhang Y, Michaelis S, Brodsky JL.

Methods Mol Med. 2002;70:257-65. No abstract available.

PMID:
11917528
8.

CFTR degradation and aggregation.

Corboy MJ, Thomas PJ, Wigley WC.

Methods Mol Med. 2002;70:277-94. No abstract available.

PMID:
11917530
9.

A domain mimic increases DeltaF508 CFTR trafficking and restores cAMP-stimulated anion secretion in cystic fibrosis epithelia.

Clarke LL, Gawenis LR, Hwang TC, Walker NM, Gruis DB, Price EM.

Am J Physiol Cell Physiol. 2004 Jul;287(1):C192-9.

10.
11.

Unusually common cystic fibrosis mutation in Portugal encodes a misprocessed protein.

Mendes F, Roxo Rosa M, Dragomir A, Farinha CM, Roomans GM, Amaral MD, Penque D.

Biochem Biophys Res Commun. 2003 Nov 21;311(3):665-71.

PMID:
14623323
12.
13.

CFTR regulation of ENaC.

Donaldson SH, Poligone EG, Stutts MJ.

Methods Mol Med. 2002;70:343-64. No abstract available.

PMID:
11917536
14.

Destabilization of the transmembrane domain induces misfolding in a phenotypic mutant of cystic fibrosis transmembrane conductance regulator.

Choi MY, Partridge AW, Daniels C, Du K, Lukacs GL, Deber CM.

J Biol Chem. 2005 Feb 11;280(6):4968-74.

16.

Correctors promote folding of the CFTR in the endoplasmic reticulum.

Loo TW, Bartlett MC, Clarke DM.

Biochem J. 2008 Jul 1;413(1):29-36. doi: 10.1042/BJ20071690.

PMID:
18361776
17.

Molecular modeling tools and approaches for CFTR and cystic fibrosis.

Serohijos AW, Thibodeau PH, Dokholyan NV.

Methods Mol Biol. 2011;741:347-63. doi: 10.1007/978-1-61779-117-8_23.

PMID:
21594796
18.

Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism.

Gelman MS, Kopito RR.

Methods Mol Biol. 2003;232:27-37. Review. No abstract available.

PMID:
12840537
19.

DeltaF508 mutation increases conformational flexibility of CFTR protein.

Wieczorek G, Zielenkiewicz P.

J Cyst Fibros. 2008 Jul;7(4):295-300. doi: 10.1016/j.jcf.2007.11.008.

20.

A monoclonal antibody prevents aggregation of the NBD1 domain of the cystic fibrosis transmembrane conductance regulator.

Lovato V, Roesli C, Ahlskog J, Scheuermann J, Neri D.

Protein Eng Des Sel. 2007 Dec;20(12):607-14.

Items per page

Supplemental Content

Support Center